Itranstad Special Precautions

Itraconazole is predominantly metabolized by the liver. The oral bioavailability in cirrhotic patients is somewhat decreased. It is advised to monitor the Itraconazole plasma concentrations and to adapt the dose when necessary.
Although Itraconazole has no relation with hepatic function disorders in patients receiving short-term therapy, it should not be administered in patients with history of hepatic diseases or hepatotoxicity caused by other drugs. It is advisable to monitor liver function in patients receiving continuous treatment of more than 1 month.
Renal impairment: The oral bioavailability of Itraconazole may be lower in patients with renal insufficiency. Monitoring of the Itraconazole plasma concentrations and a dose adaptation are advisable.
Use in children: Since clinical data on the use of Itraconazole in children is limited, it is advised that Itraconazole should not be used in these patients unless the potential benefit outweighs the potential risks.